# Subcutaneous Fluid Therapy in Dogs: Indications, Volumes, and Monitoring ## Key Takeaways - Subcutaneous fluid therapy is indicated for stable, euvolemic to mildly dehydrated canine patients with intact peripheral perfusion, serving as a maintenance intervention when continuous venous access is not feasible. - Contraindications include shock, severe dehydration, coagulopathy, severe hypothermia, and compromised skin integrity at the administration site, as these conditions impair fluid absorption and increase complication risks. - Balanced isotonic crystalloids are the preferred fluid type; avoid dextrose-containing or hypertonic solutions due to osmotic effects that delay absorption and cause tissue irritation. - Fluid volume per site is limited by patient size and skin turgor, necessitating division of the total daily volume across multiple sites (e.g., 2-4 sites) to optimize absorption and minimize discomfort. - Monitoring involves serial assessment of body weight, skin turgor, mucous membrane moisture, capillary refill time, and depot palpation every 24-48 hours to detect poor absorption or overhydration before decompensation. - Transition to intravenous fluid therapy is mandated by any deterioration in perfusion, mentation, or hydration parameters, or if subcutaneous fluid absorption is persistently poor beyond 12 hours. --- Subcutaneous fluid therapy is a maintenance intervention for stable canine patients that require ongoing hydration support without continuous venous access. This article addresses the clinical reasoning that distinguishes appropriate subcutaneous candidates from those needing intravenous resuscitation, the practical mechanics of fluid selection and volume planning, and the monitoring framework that detects failure before decompensation occurs. It is written for practicing veterinarians who make daily decisions about which patients benefit from this route and which do not. The route works because the subcutaneous space acts as a slow-release reservoir. Fluids deposited there are absorbed across capillary and lymphatic endothelium over hours, with the rate governed by the patient's hydration status, the fluid's composition, and the tissue's perfusion. This pharmacokinetic reality sets the ceiling for what subcutaneous therapy can achieve. It cannot correct shock, cannot replace rapid ongoing losses, and cannot support a patient whose peripheral perfusion is so poor that absorption stalls. The clinician's task is to match the route's limitations to the patient's physiology. ## At a Glance | Parameter | Decision Point | |---|---| | Candidate selection | Stable, euvolemic or mildly dehydrated patients with intact peripheral perfusion | | Contraindications | Shock, severe dehydration, coagulopathy, severe hypothermia, skin disease at site | | Fluid type | Balanced isotonic crystalloids, avoid dextrose-containing or hypertonic solutions | | Volume per site | Limited by patient size and skin turgor, divide total volume across multiple sites | | Absorption time | Typically 4 to 12 hours depending on hydration status and fluid volume | | Monitoring frequency | Reassess hydration, body weight, and perfusion every 24 to 48 hours | | Failure indicators | Worsening dehydration, lethargy, poor absorption, weight loss despite therapy | | Transition to IV | Any deterioration in perfusion, mentation, or hydration parameters | ## Physiology of Subcutaneous Absorption The subcutaneous space is a loose areolar network of collagen, elastin, and adipocytes, perfused by a rich subdermal capillary plexus and drained by both blood and lymphatic vessels. When isotonic crystalloid is deposited into this space, it creates a local hydrostatic pressure gradient that drives fluid into capillaries and lymphatics. The absorption rate depends on three variables: the hydrostatic pressure of the deposited fluid bolus, the oncotic and hydrostatic pressures within the local capillaries, and the integrity of the interstitial matrix itself. In a well-perfused patient, absorption proceeds steadily and predictably. In a patient with poor cardiac output or severe vasoconstriction, the capillary bed cannot accept the fluid, and the depot persists as a palpable swelling that may eventually dissect along fascial planes. This is why the route fails precisely in the patients who need fluid most urgently. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) emphasize that subcutaneous administration is appropriate only when the patient's cardiovascular status can deliver the deposited fluid into the circulation. Lymphatic uptake becomes proportionally more important as capillary absorption slows. The lymphatics are less efficient at transporting large volumes, which explains why very large subcutaneous boluses are absorbed more slowly than the same volume divided across multiple sites. The clinical implication is that volume per site matters more than total volume. A 500 mL depot in a single location will persist longer and cause more discomfort than 250 mL in two locations. ## Patient Selection and Contraindications The decision to use subcutaneous fluids begins with a perfusion assessment, not a hydration assessment. Perfusion parameters include mucous membrane color, capillary refill time, heart rate, pulse quality, and mental status. A patient with any abnormality in these parameters is not a subcutaneous candidate. The [RECOVER Initiative guidelines](https://recoverinitiative.org/) define the resuscitation phase as the period when perfusion is compromised, and subcutaneous fluids have no role in that phase because absorption cannot occur fast enough to restore circulating volume. Once perfusion is confirmed normal, the clinician assesses hydration status. Subcutaneous fluids are appropriate for patients with mild dehydration, typically estimated at less than 6 percent, or for patients with normal hydration who need ongoing maintenance support because they cannot or will not drink enough. Patients with moderate to severe dehydration, estimated at 8 percent or greater, have reduced skin turgor and peripheral perfusion that will impair absorption. These patients require intravenous therapy initially, with transition to subcutaneous fluids only after rehydration is confirmed. Additional contraindications include coagulopathies that risk hematoma formation, severe hypothermia that reduces peripheral perfusion, generalized dermatologic disease that compromises skin integrity, and patients with cardiac disease where volume loading must be precisely controlled. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) notes that the subcutaneous route provides less predictable absorption than intravenous administration, which makes it unsuitable when precise volume control is required. ## Fluid Selection and Composition Balanced isotonic crystalloids are the standard choice for subcutaneous administration. These solutions have electrolyte compositions that approximate extracellular fluid and do not create osmotic gradients that would draw water out of the vascular space. Lactated Ringer's solution and other balanced electrolyte solutions are appropriate because their buffers are metabolized once absorbed, and their sodium concentrations support extracellular volume expansion. Solutions containing dextrose should not be given subcutaneously. The osmotic effect of concentrated glucose draws fluid into the depot and delays absorption, and the resulting hypertonic environment can cause tissue irritation. Hypertonic saline has no role in subcutaneous therapy for the same reason. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) recommend isotonic crystalloids for subcutaneous maintenance and caution against additives that alter tonicity or pH. Warming fluids to body temperature before administration reduces patient discomfort and may improve absorption by preventing local vasoconstriction. The volume of fluid that can be deposited at a single site depends on patient size and skin elasticity. Small dogs may tolerate 100 to 200 mL per site, while larger dogs may accept 500 mL or more. The total daily volume should be divided across two to four sites to maximize surface area for absorption and minimize discomfort. ## Volume Planning and Administration Technique Daily maintenance fluid requirements for dogs are approximately 40 to 60 mL per kilogram per day, but this figure is a starting point, not a prescription. The clinician must add estimated ongoing losses from vomiting, diarrhea, polyuria, or fever, and subtract any oral intake the patient is reliably consuming. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) advises that fluid therapy plans be individualized and reassessed frequently, and this is particularly true for the subcutaneous route where absorption is variable. The volume administered should be the deficit plus maintenance minus oral intake, with the caveat that the subcutaneous route cannot correct a pre-existing deficit quickly. If a deficit exists, it should be small, and the clinician should expect correction over 24 to 48 hours instead of hours. The total volume is then divided into aliquots that match the patient's site capacity. Administration technique affects both comfort and absorption. The skin over the dorsal scapular region or the lateral thorax is tented to create a pocket, and a needle of appropriate gauge for the fluid viscosity is inserted into the subcutaneous space. The fluid should flow freely, resistance suggests the needle is intradermal or intramuscular. After administration, the site should be gently massaged to distribute the fluid and increase surface area for absorption. ## Monitoring the Patient During and After Administration Subcutaneous fluid therapy requires active monitoring before, during, and after administration. The clinician should establish a baseline assessment prior to the first dose, including body weight, hydration status, skin turgor, mucous membrane moisture, and capillary refill time. These parameters provide the reference points against which response to therapy is judged. During administration, observe the patient for signs of pain, excessive resistance, or leakage at the injection site. A small amount of fluid tracking along the subcutaneous plane is expected, but a visibly expanding pocket that feels tense or causes the patient to flinch or vocalize warrants immediate cessation and reassessment of needle placement. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) emphasize that patient comfort and tolerance directly influence the success of ongoing therapy, particularly when owners will be performing administrations at home. After administration, the fluid depot should be assessed at regular intervals. A soft, fluctuant swelling that gradually reduces over 4 to 12 hours indicates normal absorption. A depot that remains firm, enlarges, or becomes painful suggests poor absorption, infection, or inadvertent administration into an inappropriate tissue plane. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) notes that absorption rates vary with the fluid type, the volume administered, the site chosen, and the patient's underlying condition, so the expected resolution time must be interpreted in context. ### Monitoring Checklist for Absorption and Complications | Parameter | Assessment Method | What It Detects | Action Threshold | |---|---|---|---| | Body weight | Digital scale, same time daily | Fluid retention or loss, overhydration | Change >2% from baseline in 24 hours | | Skin turgor | Pinch and release over dorsum or forehead | Persistent dehydration, poor absorption | Tenting persists >2 seconds after 12 hours | | Mucous membranes | Visual inspection and palpation | Hydration status, perfusion | Dry, tacky, or pale beyond baseline | | Capillary refill time | Digital pressure on gingiva | Perfusion adequacy | >2 seconds or <1 second | | Depot size | Palpation and measurement | Absorption rate, leakage | No reduction in size after 12 hours | | Depot temperature | Palpation | Local inflammation, infection | Warmth or heat compared with surrounding tissue | | Injection site | Visual inspection | Hematoma, seroma, cellulitis | Erythema, discharge, or swelling beyond expected depot | | Patient demeanor | Observation and interaction | Pain, stress, systemic reaction | Reluctance to move, vocalization, hiding | | Appetite and thirst | Owner report or direct observation | Overall status, electrolyte balance | Decreased intake for 24 hours | | Urine output | Litter box or outdoor observation | Renal function, overhydration | Anuria, oliguria, or polyuria beyond baseline | Document each parameter at the time of administration and at a scheduled recheck. Serial body weight is the single most objective measure of fluid balance and should be recorded at every visit. A patient that gains weight while showing persistent clinical dehydration may be retaining fluid in the wrong compartment, which warrants reconsideration of the subcutaneous route. ## Adjusting the Plan Based on Response The initial volume calculation is a starting point, not a fixed prescription. Reassessment at 24 and 48 hours determines whether the dose should be increased, decreased, or maintained. A patient that shows improved skin turgor, brighter mentation, and stable body weight is responding appropriately. A patient that remains dehydrated despite adequate volumes may require a higher dose, a different fluid type, or transition to intravenous therapy. Poor absorption is a specific failure mode that requires prompt recognition. When the depot persists beyond 12 hours without reduction, the clinician should consider hypoproteinemia, peripheral edema, poor peripheral perfusion, or an excessively large single volume. Splitting the total daily volume into two smaller doses at different sites often improves absorption. If absorption remains inadequate after these adjustments, the subcutaneous route is not meeting the patient's needs and intravenous therapy should be pursued. Overhydration is less common with subcutaneous fluids than with intravenous therapy, but it occurs, particularly in patients with cardiac disease, renal failure, or hypoalbuminemia. Signs include chemosis, peripheral edema, tachypnea, and weight gain exceeding the administered fluid volume. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) recommend reducing or withholding the next dose and reassessing hydration status before resuming therapy. ## Documentation and Client Communication Accurate records support clinical decision-making and continuity of care. Each administration should be documented with the date, time, fluid type, volume, site, needle gauge, and any adverse reactions. The patient's weight, hydration score, and depot assessment should accompany each entry. This documentation becomes particularly valuable when therapy is continued at home, as it allows the veterinarian to compare owner-reported observations with clinical findings at recheck visits. Owner-performed administration is common in chronic disease management. A questionnaire-based study of caregivers managing feline chronic kidney disease found that approximately half of respondents administered subcutaneous fluids at home, and most reported feeling completely informed by their veterinarian about the procedure. The same study noted that a substantial minority of caregivers deviated from recommended dietary and medication protocols, which underscores the importance of clear, repeated instruction and scheduled rechecks to confirm proper technique and compliance. While this evidence comes from feline patients, the principles of caregiver education and verification apply directly to canine subcutaneous fluid therapy. Provide owners with written instructions that include the fluid type, volume, frequency, and a description of the expected depot appearance. Demonstrate the technique during the visit and observe the owner performing a practice administration before discharge. Schedule a recheck within 3 to 7 days to assess the depot, review the owner's log, and adjust the plan as needed. ## Equipment and Consumable Choices The choice of needle gauge, catheter, and administration set affects patient comfort and complication rates. For most dogs, a 20 to 22 gauge needle is appropriate, with smaller gauges reserved for small or thin patients and larger gauges for viscous fluids or rapid administration. Butterfly needles with extension tubing reduce the risk of needle dislodgement during patient movement and are particularly useful for fractions or anxious patients. Administration sets with drip chambers allow precise flow control, while syringe pumps or infusion pumps provide consistent delivery for small volumes. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) describes the range of commercially available fluid administration equipment, and the choice should be guided by the volume to be delivered, the patient's size, and the setting in which administration occurs. In a hospital setting, a fluid pump may be preferred for accuracy. At home, a simple gravity drip set with a flow regulator is often more practical and easier for owners to manage. The fluid bag and administration set should be inspected for leaks, particulate matter, and expiration date before use. Aseptic technique, including skin preparation and sterile needle handling, reduces the risk of injection site infection. The [AVMA practice resources](https://www.avma.org/resources-tools) provide general guidance on infection control in veterinary practice, and these principles apply to subcutaneous fluid administration. ## When to Stop Subcutaneous Therapy Subcutaneous fluid therapy is a maintenance and supportive modality, not a rescue intervention. The decision to discontinue should be based on objective improvement in hydration status, stable body weight, and resolution of the underlying indication. A patient that has achieved normal hydration on a stable dose for several days may be tapered by reducing the frequency or volume gradually, allowing the clinician to confirm that the patient can maintain hydration without support. Conversely, subcutaneous therapy should be stopped and replaced with intravenous therapy when the patient shows signs of shock, severe dehydration unresponsive to subcutaneous fluids, persistent vomiting that prevents oral intake, or any deterioration in cardiovascular status. The [RECOVER Initiative veterinary CPR guidelines](https://recoverinitiative.org/) address the management of cardiovascular collapse, and subcutaneous fluids have no role in resuscitation. The transition from subcutaneous to intravenous therapy should be made early instead of after the patient's condition has deteriorated further. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address animal welfare in the context of veterinary care, and the clinician should consider whether continued subcutaneous therapy is providing meaningful benefit or merely prolonging discomfort. When the underlying disease is progressive and the patient's quality of life is declining, the decision to discontinue fluid therapy should be discussed openly with the owner as part of end-of-life planning. ## Recognized Complications and Early Detection Subcutaneous fluid therapy is generally well tolerated, but complications occur and most are detected by systematic observation during and after administration. The most common failure mode is poor absorption, which presents as persistent swelling, cool skin over the depot, or fluid tracking along fascial planes. Palpation should be performed at 30 to 60 minutes after administration and again at 4 to 6 hours. A depot that remains tense and non-dependent beyond 6 hours suggests impaired uptake and warrants reassessment of the patient's hydration status, perfusion, and underlying disease. Local complications include seroma formation, cellulitis, and abscessation. Seromas develop when the needle lacerates a vessel or when fluid dissects into a pocket that cannot reabsorb. They present as fluctuant, sometimes painful swellings that persist beyond expected absorption times. Cellulitis and abscessation are typically iatrogenic, resulting from inadequate aseptic technique, repeated use of the same site, or contaminated fluid. Fever, erythema, heat, and pain on palpation are the discriminating findings. Early detection relies on daily site rotation and owner education about monitoring between visits. Needle-related injuries are underappreciated. A bent or barbed needle can lacerate subcutaneous tissue, and repeated insertion through the same skin puncture increases bacterial contamination risk. Use a fresh needle for each administration and inspect the needle before insertion. Hematoma formation is recognized by immediate bruising or swelling at the puncture site and is managed with manual pressure and site rotation. Systemic complications are less common but more serious. Fluid overload occurs when the administered volume exceeds the patient's capacity to redistribute or excrete it, particularly in patients with cardiac or renal compromise. Early signs include tachypnoea, increased lung sounds, chemosis, and peripheral edema. The 2024 AAHA/AAFP fluid therapy guidelines emphasize that even maintenance volumes can cause harm in patients with reduced cardiac reserve, and they recommend individualising volumes based on serial body weight, thoracic auscultation, and respiratory effort ([AAHA/AAFP fluid therapy guidelines for dogs and cats](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/)). Hyperthermia or hypothermia from improperly stored fluids is detected by measuring fluid temperature before administration and monitoring patient temperature afterward. ## Common Errors and Corrective Actions Less experienced clinicians frequently overestimate the volume that a given patient can absorb. A 5 kg dog with mild dehydration may tolerate 100 to 150 mL per site, but a 30 kg dog with poor skin turgor may not absorb 500 mL from a single site. The corrective action is to divide the total volume across multiple sites and to reassess absorption before repeating the dose. Another recurring error is using subcutaneous fluids as a substitute for intravenous therapy in patients with perfusion deficits. Tachycardia, prolonged capillary refill time, cold extremities, or altered mentation indicate hypovolemia that requires intravascular volume expansion. Subcutaneous administration in these patients delays definitive care. The RECOVER guidelines classify fluid administration as part of the circulation assessment in CPR and post-arrest care, but they do not support subcutaneous routes in critically compromised patients ([RECOVER Initiative veterinary CPR guidelines](https://recoverinitiative.org/)). Clinicians also err by failing to account for ongoing losses. A patient with polyuria from chronic kidney disease may need substantially more fluid than a simple maintenance calculation suggests. Serial body weight, urine output, and skin turgor should guide adjustments instead of a fixed formula. Finally, documentation errors, such as failing to record the site, volume, and time of each administration, undermine monitoring and complicate escalation decisions. ## Limitations of Current Evidence The evidence base for subcutaneous fluid therapy in dogs is largely extrapolated from clinical experience and from feline chronic kidney disease literature. A questionnaire-based study of caregivers managing feline CKD found that 50.6% of respondents administered subcutaneous fluids at home, but the study did not measure clinical outcomes, complication rates, or adherence to veterinary recommendations ([caregivers' perspectives on feline chronic kidney disease in Portugal](https://pubmed.ncbi.nlm.nih.gov/41398709/)). This highlights a genuine gap: the frequency of home administration is documented, but the safety and efficacy of long-term subcutaneous therapy in dogs are not supported by controlled trials. Expert opinion differs on several points. Some clinicians advocate routine subcutaneous fluids for stable chronic kidney disease in dogs, while others reserve the route for short-term supportive care. There is no consensus on the maximum safe volume per site, the optimal fluid temperature, or the role of subcutaneous fluids in managing hypercalcemia or electrolyte disorders. The MSD Veterinary Manual provides general guidance on fluid therapy principles but does not offer species-specific subcutaneous protocols ([MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/)). Clinicians should acknowledge this uncertainty when discussing long-term plans with owners. ## Escalation and Referral Criteria Referral or specialist consultation is warranted when a patient fails to respond to appropriately administered subcutaneous fluids, when absorption is persistently poor despite site rotation, or when complications such as abscessation, suspected fluid overload, or worsening azotaemia develop. Laboratory involvement is indicated for serial biochemistry, electrolyte monitoring, and urinalysis in patients receiving long-term therapy. Regulatory reporting is rarely relevant to subcutaneous fluid therapy, but clinicians should be aware of local requirements regarding controlled substance documentation if sedation is used for fractious patients. The AVMA practice resources provide general guidance on professional responsibilities and record keeping, but they do not address subcutaneous fluid therapy specifically ([AVMA practice resources](https://www.avma.org/resources-tools)). When in doubt about a patient's trajectory, earlier escalation is safer than delayed referral. ## Troubleshooting Table | Observation | Likely Cause | Discriminating Check | |---|---|---| | Depot persists beyond 6 hours | Impaired absorption, dehydration, or poor site selection | Palpate for tension, reassess hydration status, consider IV route | | Fever, erythema, pain at site | Cellulitis or abscessation | Check site temperature, leukogram, aspirate for cytology | | Immediate bruising or swelling | Hematoma from vessel laceration | Apply pressure, rotate site, monitor for expansion | | Tachypnoea, chemosis, peripheral edema | Fluid overload | Auscultate lungs, weigh patient, reassess cardiac status | | Cool fluid at administration | Fluid stored below body temperature | Measure fluid temperature before use, warm to 37 to 38°C | | Repeated poor absorption across sites | Underlying hypovolemia or low cardiac output | Evaluate perfusion parameters, escalate to IV therapy | ## Frequently Asked Questions ### How Should I Adjust Subcutaneous Fluid Volumes for a Patient That Is Also Receiving Oral Fluids or a Renal Diet? Total daily fluid intake is the sum of oral water, food moisture, and parenteral fluids. When a patient reliably drinks and eats wet food, reduce the subcutaneous volume by the estimated oral contribution. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) recommend reassessing maintenance needs at each visit instead of prescribing a fixed volume indefinitely. A dog consuming a moisture-rich renal diet may need 20 to 30 percent less subcutaneous volume than one eating dry kibble. Ask the owner to measure water intake for 48 hours before adjusting the dose. Recheck hydration status and body weight within 5 to 7 days of any change. ### What Are the Practical Limits of Subcutaneous Fluids in a Low-Resource or General Practice Setting? Subcutaneous therapy is well suited to practices without 24-hour hospitalization capacity. It requires only sterile fluid bags, administration sets, and needles. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) notes that subcutaneous administration is appropriate for mildly dehydrated patients with stable perfusion. When a fluid pump is unavailable, gravity flow through a 19 or 20 gauge needle is sufficient. Warm fluids to body temperature before administration to improve comfort and absorption. If sterile isotonic crystalloids are unavailable, do not substitute hypotonic or hypertonic solutions. A practice that cannot provide aseptic technique, appropriate fluids, or serial monitoring should refer the case instead of compromise patient safety. ### How Do I Explain the Transition From Subcutaneous to Intravenous Fluids to an Owner Who Prefers Home Therapy? Frame the decision around perfusion status, not owner convenience. Explain that subcutaneous fluids absorb slowly from the interstitial space, which is inadequate when blood pressure or organ perfusion is compromised. The [RECOVER Initiative guidelines](https://recoverinitiative.org/) emphasize that patients with shock or significant dehydration require rapid intravascular volume expansion that subcutaneous routes cannot deliver. Use objective language: list the specific findings that triggered escalation, such as prolonged capillary refill time, tachycardia, or a 5 percent or greater body weight loss despite home therapy. Reassure the owner that home therapy was appropriate earlier and that hospitalization is a temporary escalation, not a failure of their care. ### What Records Should I Maintain for a Patient Receiving Long-Term Subcutaneous Fluids? Document the prescribed volume, fluid type, administration frequency, and the most recent body weight at every visit. Record the owner's report of absorption time, any episodes of vomiting or swelling at the site, and the patient's appetite and activity level between visits. The [AVMA practice resources](https://www.avma.org/resources-tools) advise that medical records should support continuity of care and defend clinical decisions if outcomes are questioned. Include a subjective hydration score, skin turgor assessment, and mucous membrane evaluation in the physical examination notes. Note the rotation schedule for administration sites and any visible skin changes. If the owner administers fluids, record their technique observations and any training reinforcement provided. ### How Does Subcutaneous Fluid Therapy Differ in Cats, and Should I Apply the Same Monitoring Standards? Cats tolerate smaller volumes per site and absorb fluids more slowly than dogs. The [AAHA and AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) recommend lower per-site volumes and slower administration rates in cats to reduce discomfort and backflow. Monitoring standards should be identical: serial body weight, hydration assessment, and site inspection. A Portuguese caregiver study found that over half of owners administered subcutaneous fluids at home for feline chronic kidney disease, yet blood pressure assessment at diagnosis was confirmed in fewer than half of cases. This gap matters because hypertension commonly accompanies renal disease and can be masked by apparent clinical stability. Apply the same vigilance to cats as to dogs, and add blood pressure monitoring to the routine. ### When Should I Stop Subcutaneous Fluids Entirely instead of Reduce the Dose? Discontinue therapy when the patient maintains stable hydration, body weight, and clinical status without it for at least one week. Stop earlier if the patient develops recurrent complications such as sterile abscesses, skin necrosis, or behavioral resistance that cannot be managed with technique changes. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) identifies ongoing vomiting, diarrhea, or other ongoing fluid losses as situations where subcutaneous therapy is insufficient and intravenous support is required. If the underlying disease progresses to end-stage renal failure or another terminal condition, reassess the goals of care with the owner. Continuing subcutaneous fluids in a patient with poor quality of life, refractory nausea, or progressive cachexia may prolong suffering without meaningful benefit. Document the rationale for discontinuation in the medical record. ## Related Clinical & Scientific Guides * [Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach](/knowledge/veterinary-medicine/emergency-critical-care/toxicology-emergency-practice-common-poisons-diagnostic-approach) * [Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-cardiopulmonary-resuscitation-post-cardiac-arrest-care) * [Fluid Therapy Guidelines for Dogs and Cats: A Practical Update](/knowledge/veterinary-medicine/emergency-critical-care/fluid-therapy-guidelines-dogs-cats-practical-update) ## References and Further Reading - [Caregivers' perspectives on feline chronic kidney disease in Portugal: a questionnaire-based study.](https://pubmed.ncbi.nlm.nih.gov/41398709/). 2025. - [RECOVER Initiative Veterinary CPR Guidelines](https://recoverinitiative.org/). Veterinary Emergency and Critical Care Society. - [AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/). AAHA. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. - [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association. - [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH. ## Related Articles - [Fluid Therapy Guidelines for Dogs and Cats: A Practical Update](/knowledge/veterinary-medicine/emergency-critical-care/fluid-therapy-guidelines-dogs-cats-practical-update) - [Veterinary Fluid Therapy: Crystalloids vs Colloids](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-fluid-therapy-crystalloids-colloids) - [Veterinary Plasma Transfusion: Indications and Administration](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-plasma-transfusion-indications-administration) - [Goal-Directed Fluid Therapy in Sepsis: Resuscitation, Optimization, and Maintenance](/knowledge/veterinary-medicine/emergency-critical-care/goal-directed-fluid-therapy-sepsis-resuscitation-optimization-maintenance) - [Invasive Hemodynamic Monitoring in the Veterinary ICU](/knowledge/veterinary-medicine/emergency-critical-care/invasive-hemodynamic-monitoring-veterinary-icu) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.